|
Pfizer reports first-quarter 2014 results
|
06 May 2014 |
|
Pfizer sends letter to Rt Hon David Cameron MP regarding commitments if proposed combination with AstraZeneca is completed
|
01 May 2014 |
|
Pfizer Confirms prior discussions with AstraZeneca
|
28 April 2014 |
|
Eliquis® (apixaban) reduced the risk of stroke and demonstrated fewer major bleeding events versus Warfarin
|
23 February 2014 |
|
Pfizer and Merck to collaborate on innovative anti-cancer combination studies
|
06 February 2014 |
|
Pfizer reports fourth-quarter and full-year 2013 results
|
29 January 2014 |
|
Pfizer settles Viagra® patent litigation with Teva
|
17 December 2013 |
|
Pfizer expands clinical trial data access policy and launches data access portal
|
09 December 2013 |
|
Pfizer acquires Polocard, Poland's leading over-the-counter heart attack prevention brand
|
03 December 2013 |
|
Pfizer and GSK to initiate study of novel combination therapy in patients with melanoma
|
21 November 2013 |
|
Pfizer reports third quarter 2013 results
|
30 October 2013 |
|
International Atherosclerosis Society and Pfizer Independent Grants for Learning & Change collaborate on new grant opportunity
|
03 October 2013 |
|
Pfizer to create separate, internal, global Innovative and Value businesses
|
30 July 2013 |
|
Pfizer statement on PhRMA-EFPIA principles for responsible clinical trial data sharing
|
25 July 2013 |
|
Pfizer obtains $2.15 billion settlement from Teva and Sun for infringement of Protonix® patent
|
12 June 2013 |
|
United States Patent & Trademark Office grants Pfizer reissue patent for Celebrex®
|
05 March 2013 |
|
Pfizer and AstraZeneca enter into agreement for over-the-counter Nexium
|
13 August 2012 |
|
Pfizer reports second-quarter 2012 results
|
31 July 2012 |
|
Pfizer reports top-line results of study of Lyrica's effect on male reproduction
|
23 July 2012 |
|
Pfizer provides topline results from Phase 3 study of Torisel®
|
16 May 2012 |